oral PI3K_-selective kinase inhibitor prodrug
preclinical candidate for breast cancer
from mining of prior PI3K inh., SBDD, and opt.
J. Med. Chem., Dec. 24, 2020
Pfizer, San Diego, CA
PF-06843195
Pfizer oral PI3ka-selective kinase inhibitor prodrug
Drug Hunter